Back to Screener

Healthcare

GeneDx Holdings Corp.(WGS)

Live Price

Offline

$59.92

-1.75% today

Window Change

+13.50%

Window

May 29, 2026 → Jun 18, 2026

Market Cap
$1.99B
Revenue Growth
+40.0%
EPS Growth
+62.4%
Dividend Yield
0.0%
Sparse coverage

Historical coverage is still filling in

This 1Y daily history view is currently sparse. Use it as directional context while we continue backfilling more history.

Coverage: 15 bars · May 29, 2026 → Jun 18, 2026

Research Briefing

A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.

Decision context

Research Snapshot

GeneDx Holdings Corp. (WGS) is a Healthcare stock with a market cap of $1.99B and listed on NASDAQ. The stock last traded around $59.92 and up 13.5% across the available one-year price window (May 29, 2026 → Jun 18, 2026). Baseline metrics include revenue growth of +40.0%, EPS growth of +62.4%, a dividend yield of 0.0%. What stands out right now is revenue +40.0%, EPS +62.4%, free cash flow +142.0% with operating margin -2.9% and ROIC -2.7%. Valuation sits in the middle of the pack at price/sales 4.7. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines WGS price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.

Benchmark Comparison

Normalized Performance vs SPY

Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.

1Y shared range

WGS

—

Normalized return

SPY

—

S&P 500

Excess Return

—

Relative to SPY

WGS Max Drawdown

-7.99%

Trailing 1Y

SPY Max Drawdown

—

Trailing 1Y

Benchmark comparison is loading or unavailable right now.

Calendar-Year Returns

Uses the longest available daily history for WGS and SPY.

Calendar-year return history is still loading or unavailable.

EPS Consensus

0.81

Range 0.81 → 0.83

No analyst count

vs prior: +13.2%

Revenue Outlook

$0.2B

Range $0.2B → $0.2B

No analyst count

vs prior: +10.0%

Consensus Spread

EPS spread2.9%
Revenue spread2.2%

Lower spread suggests tighter agreement across covering analysts.

Trend

EPS trend

Consensus average across visible periods

0.81
Latest visible period
Q3 2027Q4 2028
6 visible pointstrend: +13.2%

Trend

Revenue trend

Average analyst revenue estimate

$0.2B
Latest visible period
Q3 2027Q4 2028
6 visible pointstrend: +10.0%

Timeline

Analyst forecast ladder

Sorted by period end date. Includes both cached rows and live fallbacks from FMP.

Q4 2028
Ends Dec 31, 2028
quarter
Revenue
$0.2B
$0.2B to $0.2B
EPS
0.81
0.81 to 0.83
No analyst count
EPS: No analyst count
May 3, 09:20 AM UTC
stable/analyst-estimates
Q3 2028
Ends Sep 30, 2028
quarter
Revenue
$0.2B
$0.2B to $0.2B
EPS
0.72
0.71 to 0.73
No analyst count
EPS: No analyst count
May 3, 09:20 AM UTC
stable/analyst-estimates
Q2 2028
Ends Jun 30, 2028
quarter
Revenue
$0.2B
$0.2B to $0.2B
EPS
0.43
0.43 to 0.44
No analyst count
EPS: No analyst count
May 3, 09:20 AM UTC
stable/analyst-estimates
Q1 2028
Ends Mar 31, 2028
quarter
Revenue
$0.2B
$0.2B to $0.2B
EPS
0.10
0.10 to 0.11
No analyst count
EPS: No analyst count
May 3, 09:20 AM UTC
stable/analyst-estimates
Q4 2027
Ends Dec 31, 2027
quarter
Revenue
$0.2B
$0.2B to $0.2B
EPS
0.57
0.56 to 0.58
No analyst count
EPS: No analyst count
May 3, 09:20 AM UTC
stable/analyst-estimates
Q3 2027
Ends Sep 30, 2027
quarter
Revenue
$0.2B
$0.2B to $0.2B
EPS
0.56
0.55 to 0.57
No analyst count
EPS: No analyst count
May 3, 09:20 AM UTC
stable/analyst-estimates

Next Step

Put consensus data in context

Forecasts are most valuable when they sit beside comparisons, earnings setup, and the rest of the business story.

Read the analyst forecasts guideCompare stocks with this setup